Table 4.
In vitro susceptibility patterns of Candida species isolates from gastroesophageal candidiasis
| Candida spp. | Antifungal Pattern | Antifungal Agents | ||||||
|---|---|---|---|---|---|---|---|---|
| AMB | CAS | VOR b | FLC | POS a | ITR | LLCZ a | ||
| C. albicans | S I / (SSD) R |
36 0 0 |
36 0 0 |
36 0 0 |
20 (14) 2 |
- - - |
33 (3) 0 |
- - - |
| C. glabrata | S I / (SSD) R |
0 8 0 |
8 0 0 |
- - - |
0 (8) 0 |
- - - |
3 (5) 0 |
- - - |
| C. parapsilosis | S I / (SSD) R |
2 0 0 |
2 0 0 |
1 1 0 |
1 0 1 |
- - - |
1 0 1 |
- - - |
| C. famata c | S I / (SSD) R |
- - - |
- - - |
- - - |
- - - |
- - - |
- - - |
- - - |
| Total | S I / (SSD) R |
38 8 0 |
46 0 0 |
37 1 0 |
21 (22) 3 |
- - - |
37 (8) 1 |
- - - |
S: susceptible; I: intermediate; SDD: susceptible dose dependent; R: resistant; AMB: amphotericin B; CAS: caspofungin; VOR: voriconazole; FLC: fluconazole; POS: posaconazole; ITR: itraconazole; LLCZ: luliconazole. a Posaconazole and luliconazole have no breakpoint in the new version of CLSI. b For C. glabrata and voriconazole, current data is insufficient to demonstrate a correlation between in vitro susceptibility testing and clinical outcome. c All antifungals have no breakpoints for uncommon species such as C. famata